The stock of Heska Corp (NASDAQ:HSKA) hit a new 52-week high and has $192.78 target or 187.00% above today’s $67.17 share price. The 6 months bullish chart indicates low risk for the $478.84 million company. The 1-year high was reported on Nov, 17 by Barchart.com. If the $192.78 price target is reached, the company will be worth $895.43 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 3.07% or $2 during the last trading session, hitting $67.17. About 161,239 shares traded hands or 57.21% up from the average. Heska Corp (NASDAQ:HSKA) has risen 127.55% since April 15, 2016 and is uptrending. It has outperformed by 122.93% the S&P500.
Heska Corp (NASDAQ:HSKA) Ratings Coverage
Out of 2 analysts covering Heska Corp (NASDAQ:HSKA), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Heska Corp has been the topic of 3 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The rating was upgraded by TheStreet to “Hold” on Tuesday, August 25. On Friday, April 1 the stock rating was initiated by CL King with “Neutral”. As per Thursday, August 4, the company rating was downgraded by Gabelli.
According to Zacks Investment Research, “Heska Corporation is focused on the discovery, development and marketing of companion animal health products. In addition to manufacturing certain of companion animal products, the company’s primary manufacturing subsidiary, Diamond Animal Health, Inc., also manufactures animal health vaccine products which are marketed and distributed by third parties. In addition to manufacturing veterinary allergy products for marketing and sale by the company, subsidiaries, Center Laboratories, Inc. and CMG-Heska Allergy Products S.A., also manufacture and sell human allergy products.”
Insitutional Activity: The institutional sentiment increased to 1.54 in Q2 2016. Its up 0.10, from 1.44 in 2016Q1. The ratio improved, as 6 funds sold all Heska Corp shares owned while 29 reduced positions. 24 funds bought stakes while 30 increased positions. They now own 4.56 million shares or 4.63% more from 4.36 million shares in 2016Q1.
Moreover, Blackrock Invest Llc has 0% invested in Heska Corp (NASDAQ:HSKA) for 23,140 shares. Jpmorgan Chase & Commerce accumulated 0% or 50 shares. Numeric Invsts Limited Com has 0% invested in the company for 14,336 shares. The New York-based Renaissance Tech Limited Liability has invested 0.01% in Heska Corp (NASDAQ:HSKA). Teton Advsr Incorporated has 38,000 shares for 0.13% of their US portfolio. Gamco Invsts Et Al accumulated 0.01% or 50,200 shares. The Missouri-based American Century Companies has invested 0% in Heska Corp (NASDAQ:HSKA). Blackrock Japan Com last reported 709 shares in the company. Moreover, State Common Retirement Fund has 0% invested in Heska Corp (NASDAQ:HSKA) for 5,800 shares. The New York-based Dalton Greiner Hartman Maher has invested 0.03% in Heska Corp (NASDAQ:HSKA). Strs Ohio accumulated 0% or 16,500 shares. Ameriprise Financial holds 0% of its portfolio in Heska Corp (NASDAQ:HSKA) for 35,022 shares. Credit Suisse Ag has 523,982 shares for 0.02% of their US portfolio. California Public Employees Retirement System holds 6,880 shares or 0% of its portfolio. Financial Bank Of Mellon Corp has 0% invested in the company for 79,633 shares.
Insider Transactions: Since July 1, 2016, the stock had 0 insider buys, and 14 insider sales for $6.35 million net activity. $242,134 worth of shares were sold by Wilson Kevin S. on Monday, July 18. $305,000 worth of Heska Corp (NASDAQ:HSKA) was sold by Asakowicz Steve on Monday, November 7. Another trade for 5,000 shares valued at $262,642 was made by NAPOLITANO JASON A on Thursday, September 1. McGinley Michael J sold $601,051 worth of stock or 9,998 shares. $7,028 worth of shares were sold by McMahon John on Wednesday, August 24.
More news for Heska Corp (NASDAQ:HSKA) were recently published by: Marketwatch.com, which released: “Heska downgraded to neutral from buy at B. Riley” on December 21, 2009. Quotes.Wsj.com‘s article titled: “News Heska Corp.HSKA” and published on February 12, 2011 is yet another important article.
HSKA Company Profile
Heska Corporation, incorporated on March 27, 1997, develops, makes, markets, sells and supports veterinary products. The Firm is focused on the canine and feline companion animal health markets. The Firm operates in two divisions, which include Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It sells veterinary diagnostic and other specialty veterinary products. The Company’s offerings include blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.